Were Seana Carson’s Bausch Health share sales under a Rule 10b5-1 plan?

Yes. The footnotes state that certain Bausch Health common shares sold by Seana Carson were executed in the open market pursuant to a Rule 10b5-1 plan adopted by her on May 7, 2025 , indicating a pre-arranged trading program.

What are the tax-withholding share dispositions reported for Bausch Health (BHC)?

The filing explains that some reported transactions represent common shares of Bausch Health withheld to satisfy tax withholding obligations due upon vesting of Restricted Share Units . These are not open-market sales but shares retained by the issuer to cover tax liabilities.

How were Seana Carson’s Bausch Health performance share units settled?

The document notes that 137,922 performance share unit awards earned on February 9, 2026 were disposed of in cash, following a decision to pay them in cash instead of Bausch Health common stock, under the company’s 2014 Omnibus Incentive Plan .

Bausch Health (BHC) EVP Carson trades shares, settles equity awards

Q: What insider transactions did Bausch Health (BHC) disclose for Seana Carson?

Bausch Health disclosed that EVP and General Counsel Seana Carson executed open-market sales of common shares, tax-withholding share dispositions on restricted share unit vesting, and a cash settlement of 137,922 performance share unit awards under the 2014 Omnibus Incentive Plan.

Q: How many Bausch Health (BHC) shares did Seana Carson sell in the open market?

Seana Carson reported selling 6,856 Bausch Health common shares on March 2, 2026 at $5.78 per share and 4,420 shares on March 3, 2026 at $5.77 per share, both described as open-market sales under a Rule 10b5-1 trading plan.

Q: How many Bausch Health shares does Seana Carson own after these transactions?

After the most recent reported sale on March 3, 2026 , Seana Carson directly holds 616,761 Bausch Health common shares. This post-transaction balance reflects the cumulative effect of the sales and equity-related dispositions reported in the Form 4.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Bausch Health Companies Inc. EVP and General Counsel Seana Carson reported several equity transactions in the company’s common shares. She sold 6,856 shares on March 2, 2026 at $5.78 per share and 4,420 shares on March 3, 2026 at $5.77 per share in open-market sales under a pre-arranged Rule 10b5-1 trading plan. The filing also shows share dispositions used to cover tax withholding on vesting of restricted share units, and a cash settlement of 137,922 previously earned performance share unit awards under the company’s 2014 Omnibus Incentive Plan. After the most recent sale, Carson directly holds 616,761 common shares of Bausch Health.

Insider Trade Summary

Net Seller: 11,276 shares ($65,131)

Net Sell 5 txns

Insider Carson Seana

Role EVP, General Counsel

Sold 11,276 shs ($65K)

Type	Security	Shares	Price	Value
Sale	Common Shares, No Par Value	4,420	$5.77	$26K
Sale	Common Shares, No Par Value	6,856	$5.78	$40K
Tax Withholding	Common Shares, No Par Value	16,973	$5.95	$101K
Other	Common Shares, No Par Value	137,922	$5.95	$821K
Tax Withholding	Common Shares, No Par Value	26,326	$5.93	$156K

Holdings After Transaction: Common Shares, No Par Value — 616,761 shares (Direct)

Footnotes (1)

This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Represents shares of common stock sold in the open market pursuant to a Rule 10b5-l plan adopted by the Reporting Person on May 7, 2025. This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Reflects the disposition in cash as contemplated by paragraph 7(1)(b) of the Income Tax Act (Canada) of 137,922 performance share unit awards originally granted to the Reporting Person under the Bausch Health Companies, Inc. 2014 Omnibus Incentive Plan on March 2, 2023, which, as previously reported on February 11, 2026, were earned, on February 9, 2026, upon certification by the Talent and Compensation Committee (the "Committee") of the Board of Directors of the Issuer of the level of achievement of the applicable performance metrics, but remained subject to service-based vesting. As disclosed in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 2, 2026, the Committee subsequently took action to provide for the payment of such earned performance share unit awards in cash rather than Issuer common stock upon vesting. The disposition in cash is exempt under Rule 16b-3(e). Represents shares of common stock sold in the open market pursuant to a Rule 10b5-l plan adopted by the Reporting Person on May 7, 2025.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 05:43 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carson Seana

(Last)

(First)

(Middle)

400 SOMERSET CORPORATE BOULEVARD

(Street)

BRIDGEWATER

08807

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Bausch Health Companies Inc. [ BHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares, No Par Value	02/27/2026		F		26,326⁽¹⁾	D	$5.93	782,932	D
Common Shares, No Par Value	03/02/2026		S		6,856⁽²⁾	D	$5.78	776,076	D
Common Shares, No Par Value	03/02/2026		F		16,973⁽³⁾	D	$5.95	759,103	D
Common Shares, No Par Value	03/02/2026		J		137,922⁽⁴⁾	D	$5.95	621,181	D
Common Shares, No Par Value	03/03/2026		S		4,420⁽⁵⁾	D	$5.77	616,761	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.

2. Represents shares of common stock sold in the open market pursuant to a Rule 10b5-l plan adopted by the Reporting Person on May 7, 2025.

3. This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.

4. Reflects the disposition in cash as contemplated by paragraph 7(1)(b) of the Income Tax Act (Canada) of 137,922 performance share unit awards originally granted to the Reporting Person under the Bausch Health Companies, Inc. 2014 Omnibus Incentive Plan on March 2, 2023, which, as previously reported on February 11, 2026, were earned, on February 9, 2026, upon certification by the Talent and Compensation Committee (the "Committee") of the Board of Directors of the Issuer of the level of achievement of the applicable performance metrics, but remained subject to service-based vesting. As disclosed in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 2, 2026, the Committee subsequently took action to provide for the payment of such earned performance share unit awards in cash rather than Issuer common stock upon vesting. The disposition in cash is exempt under Rule 16b-3(e).

5. Represents shares of common stock sold in the open market pursuant to a Rule 10b5-l plan adopted by the Reporting Person on May 7, 2025.

	/s/ Brianna M. Dorsi attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Bausch Health (BHC) disclose for Seana Carson?

Bausch Health disclosed that EVP and General Counsel Seana Carson executed open-market sales of common shares, tax-withholding share dispositions on restricted share unit vesting, and a cash settlement of 137,922 performance share unit awards under the 2014 Omnibus Incentive Plan.

How many Bausch Health (BHC) shares did Seana Carson sell in the open market?

Seana Carson reported selling 6,856 Bausch Health common shares on March 2, 2026 at $5.78 per share and 4,420 shares on March 3, 2026 at $5.77 per share, both described as open-market sales under a Rule 10b5-1 trading plan.

How many Bausch Health shares does Seana Carson own after these transactions?

After the most recent reported sale on March 3, 2026, Seana Carson directly holds 616,761 Bausch Health common shares. This post-transaction balance reflects the cumulative effect of the sales and equity-related dispositions reported in the Form 4.